Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Nat Med. 2023 Dec;29(12):3271. doi: 10.1038/s41591-023-02312-9. Nat Med. 2023. PMID: 36944799 No abstract available.
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Geldart T, Chester J, Casbard A, Crabb S, Elliott T, Protheroe A, Huddart RA, Mead G, Barber J, Jones RJ, Smith J, Cowles R, Evans J, Griffiths G. Geldart T, et al. Eur Urol. 2015 Apr;67(4):599-602. doi: 10.1016/j.eururo.2014.11.003. Epub 2014 Nov 20. Eur Urol. 2015. PMID: 25465968 Free PMC article. Clinical Trial.
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Bellmunt J, et al. Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021. Epub 2015 Oct 24. Eur Urol. 2016. PMID: 26508309 Free PMC article. Clinical Trial.
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Kelly JD, Tan WS, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E; BOXIT Investigators. Kelly JD, et al. Eur Urol. 2019 Apr;75(4):593-601. doi: 10.1016/j.eururo.2018.09.020. Epub 2018 Sep 29. Eur Urol. 2019. PMID: 30279015 Clinical Trial.
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ. Woods BS, et al. Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14. Eur Urol Oncol. 2018. PMID: 31158087 Free PMC article. Clinical Trial.
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N, Chi KN, Özgüroğlu M, Rodriguez-Antolin A, Feyerabend S, Fein L, Alekseev BY, Sulur G, Protheroe A, Li S, Mundle S, De Porre P, Tran N, Fizazi K. Matsubara N, et al. Eur Urol. 2020 Apr;77(4):494-500. doi: 10.1016/j.eururo.2019.11.021. Epub 2019 Dec 13. Eur Urol. 2020. PMID: 31843335 Clinical Trial.
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F, Bryant R, Pollock E, Carter L, Verrill C, Hollidge J, Poulton I, Baker M, Mitton C, Baines A, Meier A, Schmidt G, Harrop R, Protheroe A, MacPherson R, Kennish S, Morgan S, Vigano S, Romero PJ, Evans T, Catto J, Hamdy F, Hill AVS, Redchenko I. Cappuccini F, et al. J Immunother Cancer. 2020 Jun;8(1):e000928. doi: 10.1136/jitc-2020-000928. J Immunother Cancer. 2020. PMID: 32591433 Free PMC article. Clinical Trial.
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.
Szabados B, Rodriguez-Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal MJ, Suárez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T. Szabados B, et al. Eur Urol Oncol. 2021 Jun;4(3):456-463. doi: 10.1016/j.euo.2020.11.010. Epub 2021 Feb 18. Eur Urol Oncol. 2021. PMID: 33612455
134 results